Rayner Receives FDA Approval for the C-flex® Aspheric 970C IOL

Now, US surgeons can choose an aspheric IOL with both the advantages of the unique Rayner platform and a track record of successful, worldwide outcomes for both physician and patient.

Hove, UK, 7 December, 2011: Rayner Intraocular Lenses Limited, the World’s original manufacturer of IOLs, today announced receipt of FDA approval for the C-flex® Aspheric 970C for sale in the United States.

For the first time, US surgeons will be able to choose an aspheric IOL with the unique benefits of Rayner’s Anti-Vaulting Haptic technology, Rayacryl® hydrophilic acrylic material and the Amon-Apple enhanced square edge for reduced PCO rates. The C-flex® 970C boosts Rayner’s presence in the US market and will be marketed alongside Rayner’s C-flex® 570C monofocal, spherical lens that has been available in the US since 2009.

About the Rayner C-flex® Aspheric 970C IOL

The Rayner C-flex® 970C will be available in the power range: +18.0D to + 30.0D in 0.5D increments. For more technical details on the C-flex® 970C, please visit the Company’s website: www.raynersurgical.com

About Rayner Intraocular Lenses Limited

Rayner Intraocular Lenses has over sixty years’ experience of continuous design and manufacture of IOLs and has the distinction of being the only IOL manufacturer in the United Kingdom. In 1949, British surgeon Sir Harold Ridley asked Rayner to design and make the world’s first IOL.

Today, building on this pioneering work in the restoration of sight, Rayner continues to work with surgeons around the world in the development of new IOL technologies and designs.

Download Press Release PDF